Cargando…

Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report

RATIONALE: Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options. Current treatments of ATC include surgery, radiation, and chemotherapy, used in combination when possible. In the aspect of immunotherapy, the biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Luming, Li, Ling, He, Qingqing, Wang, Meng, Ma, Yunhan, Zhu, Jian, Li, Yanchen, Fu, Xiaokang, Zhang, Yaxuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360478/
https://www.ncbi.nlm.nih.gov/pubmed/34397868
http://dx.doi.org/10.1097/MD.0000000000026138
_version_ 1783737750134980608
author Zheng, Luming
Li, Ling
He, Qingqing
Wang, Meng
Ma, Yunhan
Zhu, Jian
Li, Yanchen
Fu, Xiaokang
Zhang, Yaxuan
author_facet Zheng, Luming
Li, Ling
He, Qingqing
Wang, Meng
Ma, Yunhan
Zhu, Jian
Li, Yanchen
Fu, Xiaokang
Zhang, Yaxuan
author_sort Zheng, Luming
collection PubMed
description RATIONALE: Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options. Current treatments of ATC include surgery, radiation, and chemotherapy, used in combination when possible. In the aspect of immunotherapy, the biomarker of TMB-H and MSI-H may suggest that patients benefit from pembrolizumab. Programmed cell death-ligand 1 (PD-L1) is highly expressed in ATC but has not been written into the guidelines or approved by the FDA as a biomarker for thyroid cancer immunotherapy. PATIENT CONCERNS: A 55-year-old woman was admitted to our hospital because of a slight right-sided neck enlargement in November 2019. DIAGNOSES: The clinical diagnosis was ATC, pT3bN0M0, and stage IVB. INTERVENTIONS: Oral administration of apatinib (250 mg 3 times daily) was initiated after surgery, but some unpleasant side effects emerged after 1 month of treatment. Next-generation sequencing revealed that the tumor harbored 2 mutations, HRAS p.Q61R and TP53 p.P278S, and PD-L1 staining was positive with a high expression. Thus, camrelizumab (programmed cell death protein 1 inhibitor) was combined with apatinib, and apatinib was changed to 250 mg once a day from March 2020. OUTCOMES: No adverse reactions were observed after the treatment immunotherapy combined with antiangiogenic drugs. Currently, the survival time of patients is more than 11 months, and the quality of life is not affected. CONCLUSION: This case suggests that immunotherapy in patients with ATC based upon PD-L1 evaluation provides a therapeutic option. Targeting programmed cell death protein 1/PD-L1 may provide a much-needed treatment option for patients with advanced ATC.
format Online
Article
Text
id pubmed-8360478
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-83604782021-08-17 Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report Zheng, Luming Li, Ling He, Qingqing Wang, Meng Ma, Yunhan Zhu, Jian Li, Yanchen Fu, Xiaokang Zhang, Yaxuan Medicine (Baltimore) 5700 RATIONALE: Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options. Current treatments of ATC include surgery, radiation, and chemotherapy, used in combination when possible. In the aspect of immunotherapy, the biomarker of TMB-H and MSI-H may suggest that patients benefit from pembrolizumab. Programmed cell death-ligand 1 (PD-L1) is highly expressed in ATC but has not been written into the guidelines or approved by the FDA as a biomarker for thyroid cancer immunotherapy. PATIENT CONCERNS: A 55-year-old woman was admitted to our hospital because of a slight right-sided neck enlargement in November 2019. DIAGNOSES: The clinical diagnosis was ATC, pT3bN0M0, and stage IVB. INTERVENTIONS: Oral administration of apatinib (250 mg 3 times daily) was initiated after surgery, but some unpleasant side effects emerged after 1 month of treatment. Next-generation sequencing revealed that the tumor harbored 2 mutations, HRAS p.Q61R and TP53 p.P278S, and PD-L1 staining was positive with a high expression. Thus, camrelizumab (programmed cell death protein 1 inhibitor) was combined with apatinib, and apatinib was changed to 250 mg once a day from March 2020. OUTCOMES: No adverse reactions were observed after the treatment immunotherapy combined with antiangiogenic drugs. Currently, the survival time of patients is more than 11 months, and the quality of life is not affected. CONCLUSION: This case suggests that immunotherapy in patients with ATC based upon PD-L1 evaluation provides a therapeutic option. Targeting programmed cell death protein 1/PD-L1 may provide a much-needed treatment option for patients with advanced ATC. Lippincott Williams & Wilkins 2021-08-13 /pmc/articles/PMC8360478/ /pubmed/34397868 http://dx.doi.org/10.1097/MD.0000000000026138 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 5700
Zheng, Luming
Li, Ling
He, Qingqing
Wang, Meng
Ma, Yunhan
Zhu, Jian
Li, Yanchen
Fu, Xiaokang
Zhang, Yaxuan
Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report
title Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report
title_full Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report
title_fullStr Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report
title_full_unstemmed Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report
title_short Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report
title_sort response to immunotherapy in a patient with anaplastic thyroid cancer: a case report
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360478/
https://www.ncbi.nlm.nih.gov/pubmed/34397868
http://dx.doi.org/10.1097/MD.0000000000026138
work_keys_str_mv AT zhengluming responsetoimmunotherapyinapatientwithanaplasticthyroidcanceracasereport
AT liling responsetoimmunotherapyinapatientwithanaplasticthyroidcanceracasereport
AT heqingqing responsetoimmunotherapyinapatientwithanaplasticthyroidcanceracasereport
AT wangmeng responsetoimmunotherapyinapatientwithanaplasticthyroidcanceracasereport
AT mayunhan responsetoimmunotherapyinapatientwithanaplasticthyroidcanceracasereport
AT zhujian responsetoimmunotherapyinapatientwithanaplasticthyroidcanceracasereport
AT liyanchen responsetoimmunotherapyinapatientwithanaplasticthyroidcanceracasereport
AT fuxiaokang responsetoimmunotherapyinapatientwithanaplasticthyroidcanceracasereport
AT zhangyaxuan responsetoimmunotherapyinapatientwithanaplasticthyroidcanceracasereport